Your browser is no longer supported. Please, upgrade your browser.
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.46 Insider Own15.71% Shs Outstand251.21M Perf Week51.84%
Market Cap4.15B Forward P/E4.81 EPS next Y3.17 Insider Trans0.00% Shs Float221.63M Perf Month93.03%
Income-289.80M PEG- EPS next Q3.74 Inst Own28.00% Short Float33.20% Perf Quarter92.30%
Sales41.50M P/S99.90 EPS this Y-14.80% Inst Trans0.91% Short Ratio4.72 Perf Half Y102.80%
Book/sh0.82 P/B18.57 EPS next Y15.93% ROA-52.00% Target Price- Perf Year276.05%
Cash/sh- P/C- EPS next 5Y37.00% ROE-221.90% 52W Range1.55 - 19.39 Perf YTD123.15%
Dividend- P/FCF- EPS past 5Y-11.10% ROI-91.30% 52W High-21.45% Beta2.58
Dividend %- Quick Ratio1.10 Sales past 5Y52.40% Gross Margin78.80% 52W Low882.58% ATR1.21
Employees310 Current Ratio1.20 Sales Q/Q103.40% Oper. Margin- RSI (14)82.97 Volatility20.18% 11.39%
OptionableYes Debt/Eq0.82 EPS Q/Q32.10% Profit Margin- Rel Volume7.00 Prev Close10.42
ShortableYes LT Debt/Eq0.73 Earnings- Payout- Avg Volume15.60M Price15.23
Recom2.00 SMA2087.39% SMA5097.09% SMA200108.81% Volume109,272,760 Change46.16%
Jan-21-21Initiated Alliance Global Partners Buy $35
Jul-31-20Reiterated H.C. Wainwright Buy $24 → $30
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Jan-27-21 01:06PM  
12:42PM  
07:35AM  
Jan-26-21 07:09PM  
Jan-25-21 04:22PM  
Jan-22-21 06:48AM  
Jan-19-21 05:06PM  
08:54AM  
02:06AM  
Jan-14-21 08:31PM  
Jan-10-21 05:58PM  
Jan-06-21 05:45PM  
Dec-30-20 12:48PM  
Dec-24-20 10:02AM  
Dec-23-20 02:55PM  
01:53PM  
Dec-22-20 06:59PM  
Dec-14-20 12:06AM  
Dec-10-20 09:56AM  
Dec-09-20 01:27PM  
12:25PM  
11:33AM  
09:00AM  
07:23AM  
Dec-08-20 08:06PM  
Dec-04-20 04:21PM  
01:48PM  
Dec-02-20 07:04AM  
Nov-29-20 08:19PM  
Nov-27-20 11:41AM  
10:37AM  
10:10AM  
09:58AM  
08:00AM  
Nov-23-20 04:11PM  
10:09AM  
Nov-22-20 02:27PM  
11:28AM  
07:31AM  
Nov-21-20 01:16PM  
07:28AM  
Nov-20-20 04:08PM  
10:40AM  
07:02AM  
Nov-19-20 04:24PM  
10:07AM  
Nov-16-20 10:00AM  
Nov-15-20 06:14AM  
Nov-12-20 08:31AM  
Nov-11-20 12:18PM  
09:00AM  
Nov-09-20 06:39PM  
06:16PM  
09:00AM  
Nov-06-20 12:30PM  
Nov-04-20 10:12AM  
Nov-03-20 05:45PM  
Oct-31-20 06:25AM  
Oct-29-20 09:00AM  
Oct-28-20 11:28AM  
Oct-26-20 05:45PM  
Oct-25-20 07:00AM  
Oct-22-20 04:08PM  
07:15AM  
Oct-21-20 03:50PM  
Oct-20-20 10:05AM  
Oct-19-20 01:44PM  
Oct-18-20 06:25AM  
Oct-17-20 06:11AM  
Oct-16-20 06:43PM  
09:01AM  
Oct-15-20 09:20AM  
Oct-14-20 12:00PM  
11:57AM  
Oct-13-20 08:20AM  
02:51AM  
Oct-12-20 08:01PM  
05:21PM  
Oct-09-20 07:46PM  
05:45PM  
02:09PM  
Oct-07-20 04:44PM  
03:10PM  
09:00AM  
06:00AM  
Oct-06-20 12:04PM  
11:13AM  
Oct-04-20 06:39PM  
Oct-02-20 09:57AM  
09:57AM  
09:30AM  
Sep-30-20 03:04PM  
09:50AM  
09:27AM  
09:00AM  
Sep-29-20 11:53AM  
09:05AM  
07:47AM  
Sep-28-20 11:59PM  
10:32AM  
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Followwill DormanDirectorDec 16Sale7.141,0007,1352,130Jan 26 05:24 PM
Smith Robin LDirectorMar 05Buy2.2740,00090,89660,000Mar 05 01:58 PM